A trial of LY2875358 with erlotinib for non small cell lung cancer

This trial is looking at a new drug called LY2875358 for non small cell lung cancer which has spread to other parts of the body. The cancer must have changes to genes affecting a protein called EGFR.

Erlotinib (Tarceva) is a type of biological therapy that doctors can use to treat some lung cancers. The cancer cells need to have particular proteins that erlotinib targets. But sometimes erlotinib stops working and the cancer can start to grow again. When this happens doctors say the cancer has become resistant to the drug. Researchers are looking for new treatments to help people in this situation. In this trial they are looking at a drug called LY2875358.

LY2875358 is a monoclonal antibody. These can seek out cancer cells by looking for particular proteins. The aim of this trial is to see if adding LY2875358 can delay non small cell lung cancer becoming resistant to erlotinib.